Literature DB >> 1568392

Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients.

J Papillon1, J L Chassard.   

Abstract

The study of 54 patients treated curatively by irradiation with or without surgery is reported. The crude and cancer-specific five-year survival rates are 59.2 percent and 79.7 percent. Three patients were treated palliatively. The great variation in histologic type, clinical appearance, disease stage, and patient status justifies the definition of a treatment strategy using radiotherapy, surgery, or a combination of the two methods. T1 and T2 squamous- or basal-cell carcinomas are suitable for local excision followed by irradiation or for irradiation alone. T3 tumors and Bowen's disease should be treated by irradiation first. Verrucous carcinoma is suitable for local surgery followed by irradiation. Mucoepidermoid carcinoma and T4 tumors are suitable for preoperative irradiation and delayed surgery. The optimal radiation technique consists of delivering a dose of 40 Gy in 17 days by cobalt-60 with bolus and in combination with concomitant chemotherapy (5-fluorouracil and mitomycin C). Prophylactic irradiation of the inguinal area is recommended in all NO tumors except for T1 lesions and basal-cell carcinomas.

Entities:  

Mesh:

Year:  1992        PMID: 1568392     DOI: 10.1007/bf02049397

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

Review 1.  So Now My Patient Has Squamous Cell Cancer: Diagnosis, Staging, and Treatment of Squamous Cell Carcinoma of the Anal Canal and Anal Margin.

Authors:  Cindy Kin
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

2.  Prognostic factors of squamous cell carcinoma of the anal margin treated by radiotherapy: the Lyon experience.

Authors:  Olivier Chapet; Jean-Pierre Gerard; Francoise Mornex; Silvia Goncalves-Tavan; Jean-Michel Ardiet; Anne D'hombres; Veronique Favrel; Pascale Romestaing
Journal:  Int J Colorectal Dis       Date:  2006-03-31       Impact factor: 2.571

Review 3.  Advances in the Management of Anal Cancer.

Authors:  Diana R Julie; Karyn A Goodman
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

4.  Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy.

Authors:  Veronica Dell'Acqua; Alessia Surgo; Simona Arculeo; Maria Alessia Zerella; Vincenzo Bagnardi; Samuele Frassoni; Maria Giulia Zampino; Paola Simona Ravenda; Maria Saveria Rotundo; Fatjona Kraja; Jarek Kobiela; Piotr Spychalski; Cristiana Fodor; Marianna Alessandra Gerardi; Federica Cattani; Alessia Bazani; Wanda Petz; Robert Glynne-Jones; Roberto Orecchia; Maria Cristina Leonardi; Barbara Alicja Jereczek-Fossa
Journal:  Int J Colorectal Dis       Date:  2020-02-08       Impact factor: 2.571

5.  Premalignant neoplasms and squamous cell carcinoma of the anal margin.

Authors:  Aalok Sahai; Ira J Kodner
Journal:  Clin Colon Rectal Surg       Date:  2006-05

Review 6.  Optimal treatment strategies for anal cancer.

Authors:  Shahab Ahmed; Cathy Eng
Journal:  Curr Treat Options Oncol       Date:  2014-09

7.  Mucoepidermoid carcinoma of the anal canal: A case report and review of the literature.

Authors:  Manabu Yamamoto; Keiji Hirata; Masazumi Tuneyoshi; Yoshihiro Yoshida; Hiromitsu Matsuda; Tomonobu Gion; Yohei Tominaga
Journal:  Mol Clin Oncol       Date:  2018-09-03

8.  Conservative management of a perianal rhabdomyosarcoma in a 2-year old child by Papillon's technique.

Authors:  Charlotte Demoor-Goldschmidt; Sophie Dumoucel; Christine Haie-Meder; Nadège Corradini; Marc-André Mahé; Stéphane Supiot
Journal:  Radiat Oncol       Date:  2015-05-01       Impact factor: 3.481

9.  Overview of Recent Trends in the Management of Metastatic Anal Cancer.

Authors:  Mahender Yellu; Ayham Deeb; Olugbenga Olowokure
Journal:  World J Oncol       Date:  2015-02-14

10.  Bowen's disease - a review of newer treatment options.

Authors:  Thorsten Neubert; Percy Lehmann
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.